Grammoustianou Maria, Dimitrakopoulos Foteinos-Ioannis, Koutras Angelos
Oncology Department, Sotiria General Hospital, 115 27 Athens, Greece.
Breast Cancer Survivorship Research Group, Gustave Roussy, 94805 Villejuif, France.
Cancers (Basel). 2024 May 8;16(10):1801. doi: 10.3390/cancers16101801.
Breast cancer is the most common cancer type in women. The vast majority of breast cancer patients have hormone receptor-positive (HR+) tumors. In advanced HR+ breast cancer, the combination of endocrine therapy with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors is considered the standard of care in the front-line setting. Nevertheless, resistance to hormonal therapy and CDK4/6 inhibitors eventually occurs, leading to progression of the disease. Antibody-drug conjugates (ADCs) comprise a promising therapeutic choice with significant efficacy in patients with HR+ breast cancer, which is resistant to endocrine treatment. ADCs typically consist of a cytotoxic payload attached by a linker to a monoclonal antibody that targets a specific tumor-associated antigen, offering the advantage of a more selective delivery of chemotherapy to cancer cells. In this review, we focus on the ADC mechanisms of action, their toxicity profile and therapeutic uses as well as on related biomarkers and future perspectives in advanced HR+ breast cancer.
乳腺癌是女性中最常见的癌症类型。绝大多数乳腺癌患者患有激素受体阳性（HR+）肿瘤。在晚期HR+乳腺癌中，内分泌治疗与细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制剂联合使用被认为是一线治疗的标准方案。然而，最终会出现对激素治疗和CDK4/6抑制剂的耐药性，导致疾病进展。抗体药物偶联物（ADC）是一种有前景的治疗选择，对内分泌治疗耐药的HR+乳腺癌患者具有显著疗效。ADC通常由通过连接子连接到靶向特定肿瘤相关抗原的单克隆抗体上的细胞毒性载荷组成，具有将化疗更有选择性地递送至癌细胞的优势。在本综述中，我们重点关注ADC的作用机制、毒性特征和治疗用途，以及晚期HR+乳腺癌中的相关生物标志物和未来展望。
